1. Jung MH, Choi H, Kim JY, et al. Vertebral compression fracture in cushing's syndrome with adrenal adenoma. J Korean Soc Osteoporos. 2009. 7:209–213.
Article
2. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003. 88:5593–5602.
Article
3. Mancini T, Doga M, Mazziotti G, et al. Cushing's syndrome and bone. Pituitary. 2004. 7:249–252.
4. Ohmori N, Nomura K, Ohmori K, et al. Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. Endocr J. 2003. 50:1–7.
5. Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012. 52:580–593.
Article
6. Canalis E, Bilezikian JP, Angeli A, et al. Perspectives on glucocorticoid-induced osteoporosis. Bone. 2004. 34:593–598.
Article
7. Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006. 17:144–149.
Article
8. Faggiano A, Pivonello R, Filippella M, et al. Spine abnormalities and damage in patients cured from Cushing's disease. Pituitary. 2001. 4:153–161.
Article
9. Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf). 1992. 36:229–234.
Article
10. Di Somma C, Colao A, Pivonello R, et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf). 1998. 48:655–662.
Article
11. Rehman Q, Lang TF, Arnaud CD, et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int. 2003. 14:77–81.
Article
12. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007. 357:2028–2039.
Article